MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer.

Saved in:
Bibliographic Details
Title: MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer.
Authors: Rodríguez-González FG; Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, Dr. Molewaterplein 50, Be 4.02 (lab)/4.35b (office), PO Box 2040, 3000 CA Rotterdam, The Netherlands. f.rodriguezgonzalez@erasmusmc.nl, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens JW, Foekens JA
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2011 May; Vol. 127 (1), pp. 43-51. Date of Electronic Publication: 2010 May 19.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1573-7217
DOI:10.1007/s10549-010-0940-x